{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:42:54Z","timestamp":1782452574002,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00277-020-04074-7","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T19:12:31Z","timestamp":1592680351000},"page":"1855-1862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Sequential allogeneic hematopoietic stem cell transplantation for active refractory\/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-7867","authenticated-orcid":false,"given":"Amandine","family":"Le Bourgeois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambroise","family":"Mar\u00e7ais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis Peffault","family":"de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"N\u2019Guyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Bilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9rese","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christine","family":"B\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,20]]},"reference":[{"key":"4074_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/bmt.2013.186","volume":"49","author":"P Chevallier","year":"2014","unstructured":"Chevallier P, Labopin M, Milpied N et al (2014) Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). Bone Marrow Transplant 49:361\u2013365","journal-title":"Bone Marrow Transplant"},{"key":"4074_CR2","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23:5675\u20135687","journal-title":"J Clin Oncol"},{"issue":"3","key":"4074_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C, Schleuning M, Schwerdtfeger R et al (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 108(3):1092\u20131099","journal-title":"Blood."},{"issue":"10","key":"4074_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00277-013-1790-5","volume":"92","author":"M Krejci","year":"2013","unstructured":"Krejci M, Doubek M, Dusek J, Brychtova Y, Racil Z, Navratil M, Tomiska M, Horky O, Pospisilova S, Mayer J (2013) Combination of fludarabine, amsacrine and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patient with high-risk acute myeloid leukemia. Ann Hematol 92(10):1397\u20131403","journal-title":"Ann Hematol"},{"issue":"3","key":"4074_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjh.14428","volume":"176","author":"O Ringd\u00e9n","year":"2017","unstructured":"Ringd\u00e9n O, Labopin M, Schmid C, Sadeghi B, Polge E, Tischer J, Ganser A, Michallet M, Kanz L, Schwerdtfeger R, Nagler A, Mohty M, the Acute Leukaemia Working Party of the EBMT (2017) Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoi\u00e9tic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukemia: a survey from the Acute Leukemia Working Party of EBMT. Br J Haematol 176(3):431\u2013439","journal-title":"Br J Haematol"},{"key":"4074_CR6","doi-asserted-by":"crossref","unstructured":"Steckel NK, Groth C, Mikesch JH, Trenschel R, Ottinger H, Kordelas L, Mueller-Tidow C, Schliemann C, Reicherts C, Albring JC, Silling G, Schmidt E, Berdel WE, Lenz G, Ditschkowski M, Beelen DW, Stelljes M (2018) High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukemia. Br J Haematol 180(6):840\u2013853","DOI":"10.1111\/bjh.15137"},{"issue":"12","key":"4074_CR7","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00277-018-3453-z","volume":"97","author":"H Xiao","year":"2018","unstructured":"Xiao H, Li L, Pang Y, Wu Y, Jiang Z, Liu Z, Wu J, Xiao Y, Huang F, Liu Q, Zhang H, Luo Y, Huang H (2018) Sequential treatment combining cladribine-based reinduction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia. Ann Hematol 97(12):2479\u20132490","journal-title":"Ann Hematol"},{"key":"4074_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3324\/haematol.2016.150326","volume":"102","author":"M Mohty","year":"2017","unstructured":"Mohty M, Florent M, Blaise D et al (2017) Sequential regimen of clofarabine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. Haematologica 102:184\u2013191","journal-title":"Haematologica"},{"key":"4074_CR9","doi-asserted-by":"publisher","first-page":"78489","DOI":"10.1182\/blood-2003-06-2122","volume":"103","author":"S Jeha","year":"2004","unstructured":"Jeha S, Gandhi V, Chan KW et al (2004) Clofarabine, a novel nucleoside analog is active in pediatric patients with advanced leukemia. Blood 103:78489","journal-title":"Blood"},{"key":"4074_CR10","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","volume":"24","author":"S Jeha","year":"2006","unstructured":"Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P (2006) Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24:1917\u20131923","journal-title":"J Clin Oncol"},{"key":"4074_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3324\/haematol.2012.063438","volume":"98","author":"PS Becker","year":"2013","unstructured":"Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J, Faderl S, Estey EH (2013) Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. Haematologica 98:114\u2013118","journal-title":"Haematologica"},{"key":"4074_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s12185-017-2198-0","volume":"105","author":"A Molteni","year":"2017","unstructured":"Molteni A, Riva M, Ravano E, Marbello L, Mancini V, Grillo G, Zucchetti E, Greco R, Cairoli R (2017) Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience. Int J Hematol 105:769\u2013776","journal-title":"Int J Hematol"},{"key":"4074_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0609.2012.01822.x","volume":"89","author":"P Chevallier","year":"2012","unstructured":"Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, Faul C, Guillerm G, Finke J, Huynh A, Schubert J, Kolb HJ, Polge E, Nagler A, Mohty M (2012) Clofarabine-containing conditioning regimen for allo-SCT in AML\/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 89:214\u2013219","journal-title":"Eur J Haematol"},{"key":"4074_CR14","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1002\/cam4.880","volume":"5","author":"P Chevallier","year":"2016","unstructured":"Chevallier P, Labopin M, Peffault De Latour R et al (2016) Clofarabine versus Fludarabine-based reduced-intensity conditioning regimenprior allogeneic transplantation in adult with AML\/MDS. Cancer Medecine 5:3068\u20133076","journal-title":"Cancer Medecine"},{"key":"4074_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:695\u2013706","journal-title":"Stat Med"},{"key":"4074_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, W\u00f6lfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JLM, Levine JE (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 22:4\u201310","journal-title":"Biol Blood Marrow Transplant"},{"key":"4074_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers MED (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 11:945\u2013956","journal-title":"Biol Blood Marrow Transplant."},{"key":"4074_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A et al (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 125:1333\u20131338","journal-title":"Blood."},{"key":"4074_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A (2016) Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant 51:610\u2013611","journal-title":"Bone Marrow Transplant"},{"key":"4074_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/bmt.2017.8","volume":"52","author":"B Gyurkocza","year":"2017","unstructured":"Gyurkocza B, Lazarus HM, Giralt S (2017) Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone Marrow Transplant 52:1083\u20131090","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4074_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/ajh.25004","volume":"93","author":"J Decroocq","year":"2018","unstructured":"Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N (2018) Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory of relapsed acute myeloid leukemia: a study from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire. Am J Hematol 93(3):416\u2013423. https:\/\/doi.org\/10.1002\/ajh.25004","journal-title":"Am J Hematol"},{"issue":"4","key":"4074_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41409-018-0288-0","volume":"54","author":"V Sheth","year":"2019","unstructured":"Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A, Mayer J, Labussi\u00e8re-Wallet H, Bittenbring J, Shouval R, Savani B, Mohty M, Nagler A (2019 Apr) Comparison of FLAMSA-based reduced intensity conditioning with treosulfan\/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP\/EBMT analysis. Bone Marrow Transplant 54(4):531\u2013539","journal-title":"Bone Marrow Transplant"},{"key":"4074_CR23","doi-asserted-by":"publisher","unstructured":"Brissot E, Labopin M, Ehninger G et al (2018) Haploidentical versus unrelated allogeneic stem cell transplantation for relapse\/refractory acute myeloid leukemia: a report of 1578 patients from the Acute Leukemia Working Party of EMBT. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2017.187450","DOI":"10.3324\/haematol.2017.187450"},{"key":"4074_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.bbmt.2018.01.005","volume":"24","author":"R Dul\u00e9ry","year":"2018","unstructured":"Dul\u00e9ry R, M\u00e9nard AL, Chantepie S, el-Cheikh J, Fran\u00e7ois S, Delage J, Giannotti F, Ruggeri A, Brissot E, Battipaglia G, Malard F, Belhocine R, Sestili S, Vekhoff A, Delhommeau F, Reman O, Legrand O, Labopin M, Rubio MT, Mohty M (2018) Sequential conditioning with thiotepa in T cell- replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, haplo-mismatched, and unrelated donors. Biol Blood Marrow Transplant. 24:1013\u20131021","journal-title":"Biol Blood Marrow Transplant."},{"key":"4074_CR25","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","volume":"54","author":"T Guillaume","year":"2019","unstructured":"Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, Chevallier P, Vigouroux S, Peterlin P, Garnier A, Rubio MT, Huynh A, Milpied N, Moreau P, Gaugler B, Yakoub-Agha I, Mohty M (2019) Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54:1815\u20131826. https:\/\/doi.org\/10.1038\/s41409-019-0536-y","journal-title":"Bone Marrow Transplant"},{"key":"4074_CR26","doi-asserted-by":"publisher","unstructured":"Battipaglia G, Massoud R, Ahmed SO et al (2019) Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 mutated acute myeloid leukemia: an update. Clin Lymphoma Myeloma Leuk. https:\/\/doi.org\/10.1016\/j.clml.2019.04.004","DOI":"10.1016\/j.clml.2019.04.004"},{"issue":"1","key":"4074_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-017-0498-8","volume":"10","author":"E Brissot","year":"2017","unstructured":"Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Sch\u00e4fer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kr\u00f6ger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A (2017) Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol 10(1):130. https:\/\/doi.org\/10.1186\/s13045-017-0498-8","journal-title":"J Hematol Oncol"},{"key":"4074_CR28","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","volume":"118","author":"AH Elmaagacli","year":"2011","unstructured":"Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M, Christoph S, Gromke T, Kordelas L, Ottinger HD, Ross RS, Horn PA, Schnittger S, Beelen DW (2011) Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 118:1402\u20131412","journal-title":"Blood."},{"key":"4074_CR29","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","volume":"122","author":"ML Green","year":"2013","unstructured":"Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh M (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 122:1316\u20131324","journal-title":"Blood."},{"key":"4074_CR30","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"K Takenaka","year":"2015","unstructured":"Takenaka K, Nishida T, Asano-Mori Y et al (2015) Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant. 21:2008\u20132016","journal-title":"Biol Blood Marrow Transplant."},{"key":"4074_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbmt.2013.11.004","volume":"20","author":"AH Elmaagacli","year":"2014","unstructured":"Elmaagacli AH (2014) CMV and relapse: what has conditioning to do with it? Biol Blood Marrow Transplant. 20:1\u20132","journal-title":"Biol Blood Marrow Transplant."},{"key":"4074_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbmt.2003.08.011","volume":"10","author":"R Nakamura","year":"2004","unstructured":"Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ (2004) Persisting post transplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biology of Blood and Marrow Transplantation 10:49\u201357","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"4074_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.12875","volume":"166","author":"M Jeljeli","year":"2014","unstructured":"Jeljeli M, Gu\u00e9rin-El Khourouj V, Porcher R et al (2014) Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children. Br J Haematol 166:229\u2013239","journal-title":"Br J Haematol"},{"key":"4074_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbmt.2013.10.003","volume":"20","author":"S Manjappa","year":"2014","unstructured":"Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R (2014) Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant. 20:46\u201352","journal-title":"Biol Blood Marrow Transplant."},{"key":"4074_CR35","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1002\/ajh.23998","volume":"90","author":"A Busca","year":"2015","unstructured":"Busca A, Passera R, Pini M, Zallio F, Dellacasa C, Audisio E, Giaccone L, Maffini E, Costa C, Cavallo R, Bruno B (2015) The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors. Am J Hematol 90:E117\u2013E121","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04074-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T23:14:53Z","timestamp":1624144493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04074-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,20]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4074"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04074-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,20]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients gave informed consent for collection of their personal data in the PROMISE data base.The study has been approved by the ethics committee of the STGM-TC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}